You are here: Industry Insights > CKD

News List

Treatment for dialysis patients with CKD anaemia approved in Japan europeanpharmaceuticalreview
September 23, 2019
A treatment for anaemia associated with chronic kidney disease in dialysis patients has been approved in Japan.
Gout May Up Risk for Progression of Chronic Kidney Disease drugs
September 10, 2019
Gout is associated with an elevated risk for chronic kidney disease (CKD) progression, according to a study published online in BMJ Open.
Licence extension submission accepted for kidney disease treatment by EMA europeanpharmaceuticalreview
August 29, 2019
The licence extension submission for Invokana and Vokanamet has been accepted by the EMA.
Uncontrolled Diabetes, Hypertension Rates High in CKD Patients drugs
July 12, 2019
Uncontrolled Diabetes, Hypertension Rates High in CKD Patients.
Peripherally Inserted Central Catheters Often Used in CKD drugs
June 04, 2019
Peripherally Inserted Central Catheters Often Used in CKD.
Atrasentan Tied to Lower Risk for Kidney Events in T2DM With CKD drugs
April 22, 2019
Atrasentan is associated with a reduced risk for renal events in patients with type 2 diabetes and chronic kidney disease, according to a study published online...
Secondhand Smoke Exposure Linked to Chronic Kidney Disease drugs
March 08, 2019
Secondhand smoke exposure is associated with an increased prevalence of chronic kidney disease (CKD) and CKD development, according to a study published online March 7 in the Clinical Journal of the American Society of Nephrology.
Exome Sequencing Beneficial for Pediatric Kidney Recipients drugs
January 23, 2019
Whole-exome sequencing (WES) can identify a genetic cause for almost one-third of pediatric kidney transplant recipients, according to a study published online Jan. 17 in the Journal of the American Society of Nephrology....
DiaMedica pulls off IPO to fund midphase stroke trial fiercebiotech
December 28, 2018
DiaMedica Therapeutics has wrapped up its IPO. The offering gives DiaMedica the cash to take its lead candidate through phase 2 trials in acute ischemic stroke (AIS) and chronic kidney disease (CKD).....
AstraZeneca and FibroGen receive approval to market roxadustat in China pharmaceutical-technology
December 21, 2018
AstraZeneca and its partner FibroGen Medical Technology Development have obtained approval from China’s National Medical Products Administration (NMPA) to market roxadustat for the treatment of anaemia caused due to chronic kidney disease (CKD).....

Previous page 1 2 3 4 5 6 Next page